CONFERENCE SPEAKERS

Speakers
Althea Lang
Althea Lang
Scientific Project Manager,
Foundation for the National Institutes of Health


Neelam Bhardwaj
Neelam Bhardwaj
Product Development Lead,
Novartis


Frank Borriello
Frank Borriello
Founder and CEO,
Alloplex Biotherapeutics

Dr. Borriello is Harvard Trained Pathologist having trained at the Brigham and Women’s Hospital in the division of immunology where he worked with Arlene Sharpe and Gordon Freeman on the B7-CD28 pathway; co-authoring several pivotal papers in the costimulatory field. He obtained his MD, PhD degrees at the Albert Einstein College of Medicine in NYC where he also worked with Dr. Stanley Nathenson on structure-function relationships in the MHC Class I surface antigens. Dr. Borriello transitioned from academic life to the pharmaceutical/financial sectors in 1999 and has been a pharma business development professional since 2006.  In 2016, he was the head of search and evaluation at Baxalta across multiple therapeutic areas until the Shire acquisition, after which he left to found Alloplex Biotherapeutics in pursuit of an idea of his own invention in tumor immunology.  He currently lives with his wife and daughter in the Boston area.


Melis McHenry
Melis McHenry
Associate Director, Precision Medicine CDx,
Regeneron


Cecilia Schott
Cecilia Schott
Vice President, Global Head Precision Diagnostics,
Novartis AG


Nirmit Kumar
Nirmit Kumar
Senior Global Medical Affairs Leader, Diagnostic Oncology,
AstraZeneca


Mario Flores
Mario Flores
Assistant Professor, Department of Biomedical Engineering,
The University of Texas at San Antonio


Wenting Wang
Wenting Wang
Oncology Biomarker Statistics Team Lead,
Sanofi


Amanda Acerbi
Amanda Acerbi
Precision Medicine Global Director,
Janssen


Bhaskarjyoti Sarmah
Bhaskarjyoti Sarmah
Associate Scientific Director, Clinical Biomarkers,
Moderna


Siamak Tabrizi
Siamak Tabrizi
Senior Scientist,
Immunitas Therapeutics


Claudio Scuoppo
Claudio Scuoppo
Principal Scientist,
Sapience Therapeutics


Rakesh Dixit
Rakesh Dixit
CEO,
Bionavigen

Rakesh Dixit is a President & CEO, BIONAVIGEN, LLC, a biopharmaceutical virtual drug development company specializing in advising and consulting for all aspects of drug development, including discovery, preclinical development, CMC, translational sciences, clinical development and regulatory filing. Accomplished executive, inventor, and scientist with over 30 years of success with top biotechnology and pharmaceutical companies, including Merck, Johnson & Johnson, Medimmune, AstraZeneca.


Lindsay Darling
Lindsay Darling
Director, Companion Diagnostics Portfolio Management & Operations,
Regeneron


Russell Weiner
Russell Weiner
Head Oncology and Cell Therapy Clinical Biomarker Sciences,
Takeda